Alluvi, formerly BI 4744, offers a promising advance in obesity care. This dual agonist targeting both GLP-1 and GIP targets demonstrates remarkable efficacy in patient trials, arguably exceeding current GLP-1 target https://alluvi-research.co.uk/product/tirzepatide-40mg-rd-only-alluvi/